



HAL
open science

Proprotein convertase PCSK9 affects expression of key surface proteins in human pancreatic beta cells via intracellular and extracellular regulatory circuits

Kevin Saitoski, Maria Ryaboshapkina, Ghaith Hamza, Andrew Jarnuczak, Claire Berthault, Françoise Carlotti, Mathieu Armanet, Kaushik Sengupta, Christina Rye Underwood, Shalini Andersson, et al.

► To cite this version:

Kevin Saitoski, Maria Ryaboshapkina, Ghaith Hamza, Andrew Jarnuczak, Claire Berthault, et al.. Proprotein convertase PCSK9 affects expression of key surface proteins in human pancreatic beta cells via intracellular and extracellular regulatory circuits. *Journal of Biological Chemistry*, 2022, 298 (7), pp.102096. 10.1016/j.jbc.2022.102096 . hal-03960187

HAL Id: hal-03960187

<https://hal.science/hal-03960187>

Submitted on 22 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Proprotein convertase PCSK9 affects expression of key surface proteins in human pancreatic beta cells via intra- and extracellular regulatory circuits.

Kevin Saitoski¹, Maria Ryaboshapkina², Ghaith M. Hamza^{3,4}, Andrew F. Jarnuczak⁵, Claire Berthault¹, Françoise Carlotti⁶, Mathieu Armanet⁷, Kaushik Sengupta⁸, Christina Rye Underwood⁹, Shalini Andersson¹⁰, Isabelle Guillas¹¹, Wilfried Le Goff¹¹, Raphael Scharfmann^{1*}

¹ Université de Paris, Institut Cochin, INSERM U1016, CNRS UMR 8104, 75014 Paris, France.

² Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

³ Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States

⁴ Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824, USA

⁵ Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

⁶ Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.

⁷ Cell Therapy Unit, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France.

⁸ Alliance Management, Business Development and Licensing, Biopharmaceuticals R&D, Astra Zeneca, Gothenburg, Sweden

⁹ Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

¹⁰ Oligonucleotide Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

¹¹ Sorbonne Université, Inserm, Institute of Cardiometabolism and Nutrition (ICAN), UMR_S1166, F-75013 Paris, France

* corresponding author

Institut Cochin, INSERM U1016, 123 bd du Port-Royal, 75014 Paris, France.

Phone: 33.1.76535568

Email: raphael.scharfmann@inserm.fr

Running title: PCSK9 and pancreatic beta cells

Keywords Human pancreatic beta cell, PCSK9, LDLR, CD36, PDL1, HLA-ABC

Abstract

Proprotein convertase subtilisin/kexin 9 (PCSK9) is involved in the degradation of the low-density lipoprotein receptor (LDLR). PCSK9 also targets proteins involved in lipid metabolism (VLDLR), immunity (MHC-I), and viral infection (CD81). Recent studies have also indicated that PCSK9 loss-of-function mutations are associated with an increased incidence of diabetes; however, the expression and function of PCSK9 in insulin-producing pancreatic beta cells remain unclear. Here we studied PCSK9 regulation and function by performing loss-and gain-of-function experiments in the human beta cell line EndoC- β H1. We demonstrate that PCSK9 is expressed and secreted by EndoC- β H1 cells. We also found that PCSK9 expression is regulated by cholesterol and by sterol regulatory element binding protein (SREBP) transcription factors, as previously demonstrated in other cell types such as hepatocytes. Importantly, we show PCSK9 knockdown using siRNA results in deregulation of various elements of the transcriptome, proteome, and secretome, and increases insulin secretion. We also observed that PCSK9 decreases LDLR and VLDLR levels via an extracellular signaling mechanism involving exogenous PCSK9, as well as levels of CD36, a fatty acid transporter, through an intracellular signaling mechanism. Finally, we found PCSK9 regulates the cell surface expression of PDL1 and HLA-ABC, proteins involved in cell-lymphocyte interaction, also via an intracellular mechanism. Collectively, these results highlight PCSK9 as a regulator of multiple cell surface receptors in pancreatic beta cells.

Introduction

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the last discovered member of the proconvertases family (1). It is mainly expressed in liver, cerebellum, lung and organs of the gastrointestinal tract including pancreas (<https://gtexportal.org/home/gene/PCSK9>) (2). Hepatocytes express the highest levels of PCSK9 and are the source of circulating PCSK9 (3). PCSK9 is synthesized as an immature zymogen precursor and is autocatalytically cleaved in the endoplasmic reticulum between its N-terminal pro-domain and catalytic domain (4). The resulting mature PCSK9 is next released into the circulation where it plays a key role in the regulation of cholesterol homeostasis (3, 4).

Regulation of PCSK9 expression has been deeply studied in hepatocytes (4) and it was found that PCSK9 promoter contains a Sterol Regulatory Element (SRE) (5, 6). There, PCSK9 expression is dependent on both SREBP-1 and SREBP-2, while its regulation by cholesterol is predominantly SREBP-2 dependent (5, 6). PCSK9 expression is also modulated by insulin in a SREBP-1c dependent manner (7).

PCSK9 gain-of-function mutations are associated with familial hypercholesterolemia (8) while patients with loss-of-function PCSK9 mutations have reduced circulating LDL-cholesterol levels (9). These discoveries led to validation of PCSK9 as a therapeutic target for the treatment of hypercholesterolemia. The first anti-PCSK9 monoclonal antibodies were approved for the treatment of hypercholesterolemia in 2015 (10) and recently, small interfering RNAs targeting intracellular PCSK9 were approved by the European Medicines Agency (EMA) for the treatment of hypercholesterolemia or mixed dyslipidemia (11). Interestingly, PCSK9 loss-of-function mutations are associated with increased prevalence of type 2 diabetes (12). However, there is currently no evidence of an effect of anti-PCSK9 inhibitory antibodies on the transition to new onset diabetes, suggesting that reducing circulating PCSK9 does not impair pancreatic beta cell function (13, 14).

It is known that PCSK9 binds extracellularly to the Low Density Lipoprotein (LDL) Receptor (LDLR) and targets it for lysosomal degradation, preventing its recycling to the plasma membrane (4). In addition, a number of studies suggest that PCSK9 can also decrease LDLR abundance at the cell surface prior to its secretion via an intracellular route. Indeed, PCSK9 and LDLR interact early in the secretory pathway (15) and PCSK9 favors LDLR degradation even when its endocytosis is blocked (16). Moreover, inhibition of LDLR traffic between the trans Golgi network and the lysosome abolishes PCSK9 induced LDLR degradation (17).

In addition to LDLR, PCSK9 enhances the degradation of other proteins: Very Low Density Lipoprotein Receptor (VLDLR), LDL-related protein-8 (LRP8 also called ApoER2) (18), Cluster of differentiation 81 (CD81) (19), LDL-related protein-1 (LRP1) (20), Cluster of differentiation 36 (CD36) (21), β -secretase 1 (BACE1) (22) as well as the epithelial sodium channel subunits (SCNN1A, SCNN1B and SCNN1G, also called α -, β - and γ -ENaC) (23). Very recently, it was also demonstrated that PCSK9 disrupts the recycling of major histocompatibility complex (MHC-I) to the cell surface, thus positioning PCSK9 inhibitors as a new way to enhance immune checkpoint therapy for cancer (24). Some of the above-described proteins including the LDLR have been shown to be regulated by PCSK9 both intracellularly and extracellularly (18–21, 24). For other proteins such as BACE1, intracellular PCSK9-mediated protein degradation has been described as an important route (22). Moreover, it is the unique route for the epithelial sodium channel ENaC degradation by PCSK9 (23). Finally, for other proteins, their route of degradation by PCSK9 is far less studied.

The islets of Langerhans are micro-organs distributed throughout the pancreas. They contain beta, alpha, delta, PP and epsilon endocrine cells that produce and release insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin, respectively. PCSK9 was previously described as expressed in mouse and human pancreatic islets (25, 26). However, the precise cell type expressing PCSK9 within islets remains unclear. Some studies demonstrate that PCSK9 is only expressed in somatostatin-

producing delta cells (25, 27), while other studies indicate that beta cells express PCSK9 (26, 28, 29). The function of PCSK9 within islets is also debated.

The aim of this study was to clarify the role of PCSK9 in pancreatic beta cells. We hypothesized that PCSK9 is expressed in pancreatic beta cells and asked whether it regulates other proteins beyond LDLR.

We studied PCSK9 expression in alpha, beta and delta cell populations purified by FACS from mouse pancreatic islets. We demonstrate that *PCSK9* mRNA is enriched in the beta cell population. By using the human pancreatic beta cell line EndoC- β H1 (30), we investigated PCSK9 expression, function and its regulation. We show that PCSK9 is expressed and secreted by human pancreatic beta cell. In EndoC- β H1 cells, PCSK9 expression is regulated by cholesterol, lipoproteins and by SREBPs transcription factors. We characterized transcriptome, proteome and secretome of EndoC- β H1 cells following PCSK9 knockdown that revealed multiple deregulations. We also observed an increase in basal and glucose stimulated insulin secretion. Finally, we performed gain- and loss-of-function experiments using siPCSK9 or recombinant PCSK9 treatments to search for additional proteins regulated by PCSK9 in human beta cells. We demonstrate that PCSK9 regulates LDLR and VLDLR, two lipoproteins receptors through extracellular mechanism, and CD36, a fatty acid transporter, through an intracellular mechanism. Finally, PCSK9 regulates through an intracellular mechanism cell surface expression of PDL1 and HLA-ABC that are involved in cell-lymphocytes interaction.

Taken together, our work identifies new cell surface proteins regulated by PCSK9 and provides new insights for the comprehension of the consequences of PCSK9 modulation on beta cell function.

Results

PCSK9 is expressed and secreted by pancreatic beta cells

The cell types expressing PCSK9 in mouse and human pancreatic islets remain debated (25–28). Here, we first analyzed *PCSK9* expression in mouse pancreatic islet cell types by using a FACS-based strategy to purify beta, alpha and delta cell populations (**Fig. S1a**) (30). RT-qPCR analyses indicated that alpha (CD71⁻), beta (CD71⁺) and delta (CD24⁺) populations were highly enriched in *glucagon*, *insulin-1* and *somatostatin* mRNA, respectively, validating the efficiency of the sorting (**Fig. S1b**). *PCSK9* mRNA analyses indicated that its expression was 3-fold higher in beta than in the delta and alpha cell populations (**Fig. 1a**). *PCSK9* mRNA level was also twofold lower in beta cells than in mouse liver (**Fig. 1a**). We then compared *PCSK9* mRNA expression by RT-qPCR in human islet preparations versus human primary hepatocytes and HEK293T cells (used as positive and negative controls, respectively). *PCSK9* mRNA were detected in human islets, although at a level fivefold lower than in human primary hepatocytes. As expected, *PCSK9* was almost undetectable in HEK293T cells (**Fig. 1b**). We next investigated PCSK9 expression in human islet cell types. Since PCSK9 expression in bulk islets was low, it may be difficult to capture with single-cell sequencing due to limitations of the technology. Therefore, we used a combination of scRNA-seq (E-MTAB-5061 (31), GSE81608 (32), GSE86469 (33)) and RNA-seq on highly purified FACS sorted human beta and alpha cells (GSE67543 (34)) to analyze PCSK9 expression. *PCSK9* transcripts were enriched in human adult beta cells (**Fig. S1c**). PCSK9 function was extensively studied in the human hepatoma cell line HepG2. We compared PCSK9 expression between EndoC- β H1, HepG2 and HEK293T cells. There, *PCSK9* mRNA level was higher than in the human hepatoma cell line HepG2 (**Fig. 1c**). We next studied PCSK9 expression by Western blot (see **Fig. S2a-e** for antibody validation). Western blot analysis revealed the presence of two major PCSK9 bands at ~75 kDa and ~60 kDa. These bands corresponded to the expected sizes for pro-PCSK9 and mature PCSK9. Quantification of mature PCSK9 level showed a 3-fold higher expression in EndoC- β H1 compared to HepG2 cells, and no expression in HEK293T cells (**Fig. 1d and e**). Noteworthy, PCSK9 maturation rate (as measured by the mature PCSK9/total PCSK9 ratio) was

higher in HepG2 cells than in the EndoC- β H1 (**Fig. S1d**). Given the fact that PCSK9 is a secreted protein, we also compared by Western blot PCSK9 levels in conditioned media from EndoC- β H1, HepG2 and HEK293T cells. In EndoC- β H1 and HepG2 cells, we detected a single band at approximately 60 kDa (as expected for the secreted mature form of PCSK9) and no signal in conditioned media from the HEK293T cells (**Fig. 1f**). PCSK9 secretion was twice lower in EndoC- β H1 when compared to HepG2 cells (**Fig. 1f and g**). It was also the case when PCSK9 secretion was normalized to PCSK9 cell content (**Fig. S1e**). Finally, as *PCSK9* transcripts were present in human islet preparations (**Fig. 1b**), we evaluated whether PCSK9 was secreted by human islets. By Western blot, we detected in conditioned media the presence of a band at ~60 kDa, the expected size for the secreted form of PCSK9 (**Fig. 1h**). Omics data analysis confirmed that EndoC- β H1 cells are a representative *in vitro* model for human beta cells (35). Thus, mouse and human beta cells express PCSK9, and EndoC- β H1 cells can be used as a model to study PCSK9 regulation and function in human beta cells.

Cholesterol, LDL and Mevastatin modulate PCSK9 expression and secretion

In mouse and human hepatocytes, PCSK9 expression is regulated by cholesterol and by lipid-lowering drugs of the statin class (5, 36). Here, we evaluated the effects on PCSK9 expression of cholesterol, LDL and Mevastatin in EndoC- β H1 cells. Concentrations were chosen based on their effect on *HMGCR* gene expression, a SREBP-2 transcriptional target (**Fig. S3a-d**). Cholesterol and LDL treatments reduced the mRNA expression of both SREBP2 (*HMGCR* and *LDLR*) and SREBP1 (*FASN* and *SCD*) transcriptional targets by ~50%. Mevastatin treatment increased the expression of these genes by at least two-fold, demonstrating the functionality of the LDL-cholesterol pathway in EndoC- β H1 cells (**Fig. 2a**). *PCSK9* mRNA followed a similar pattern as expression was reduced by cholesterol and LDL treatment and increased following incubation with Mevastatin (**Fig. 2b**). The effects of Mevastatin were reverted by cholesterol or LDL treatments and were thus “cholesterol specific” (**Fig. 2a, b**). Similar effects of cholesterol, LDL and Mevastatin were also observed at protein level. Indeed,

Western blot analyses indicated that cholesterol and LDL treatments decreased, while Mevastatin increased intracellular PCSK9 levels (**Fig. 2c and d**). Similar results were also obtained when secreted PCSK9 was analyzed (**Fig. 2e and f**). Finally, we tested whether other classes of human lipoproteins modulate *PCSK9* expression in EndoC- β H1 cells. Treatment with Triglyceride-Rich Lipoproteins (TRL) mimicked the effects of *LDL* on *PCSK9* mRNA expression and on *SREBP-1* and *SREBP-2* transcriptional targets while oxidized LDL had no effect (**Fig. 2g, h**).

PCSK9 is regulated by the SREBPs-1 and 2 transcription factors

We first tested whether *PCSK9* mRNA levels were dependent on SREBPs transcription factors. Co-transfection of the EndoC- β H1 cells with siSREBF-1+siSREBF-2 efficiently reduced mRNA expression of *SREBF-1*, *SREBF-2* and their respective target genes: *FASN*, *SCD* (SREBP-1 targets) and *HMGCR*, *LDLR* (SREBP-2 targets). *PCSK9* mRNA levels were downregulated indicating dependence of SREBPs activity (**Fig. 3a**). Single siSREBF-2 downregulated *SREBF-2* and its target *HMGCR*, but not *SREBF-1*. It increased *PCSK9* mRNA levels (**Fig. 3b**). Single siSREBF-1 transfection specifically reduced *SREBF-1* expression. The expression of canonic SREBP-1 liver targets *FASN* and *SCD* was not modulated, indicating the existence of compensatory mechanism that maintain *FASN*, *SCD* and *LDLR* expression when *SREBF-1* or *SREBF-2* are reduced following knockdown (**compare Fig. 3a to 3b and 3c**). On the other hand, *SREBF-1* knockdown was sufficient to decrease *PCSK9* expression, indicating that *SREBF-1* is essential to maintain *PCSK9* expression (**Fig. 3c**).

We next assessed the SREBPs dependence of *PCSK9* upon Mevastatin treatment. As expected, Mevastatin treatment increased the mRNA expression of SREBP-1 targets, SREBP-2 targets and also *PCSK9* (**Fig. 3d**). This induction was reverted upon SREBF-1+2 double knockdown (**Fig. 3e**). Single SREBF-2 knockdown reduced the expression of *SREBF-2* and its target genes *HMGCR* and *LDLR* in presence of Mevastatin. *PCSK9* expression was also down-regulated suggesting a SREBP-2 dependence (**Fig. 3f**). However, we noted that upon Mevastatin treatment, siSREBF-2 decreased *SREBF-1* levels (**Fig. 3f**). We thus performed single siSREBF1 knockdown that did not modulate *PCSK9*

expression (**Fig. 3g**). Taken together, our data indicate that SREBP-2, but not SREBP-1 is involved in the induction of PCSK9 by Mevastatin in human beta cells.

Insights from hypothesis-generating omics analysis

We investigated the effect of siRNA-mediated PCSK9 knockdown in EndoC- β H1 cells in transcriptomics and proteomics experiments. PCSK9 knockdown was confirmed in all omics experiments (**Fig. S4**). Changes in gene and protein expression levels were generally consistent and had the same directionality (60.3% for RNA-seq vs DIA cell lysate proteomics and 59.7% for RNA-seq vs TMT cell lysate proteomics) (**Fig. S5**). IPA Pathway enrichment analysis indicated impaired mitochondrial function (**Fig. 4a**) which was confirmed by GSEA analysis (**Fig 4b**). Normal mitochondrial function is crucial for insulin secretion by beta cells (37). We investigated the expression of markers associated with glucose-stimulated insulin secretion (38). Out of 147 markers, 45 (31%) were differentially expressed (**Fig. 4c**). We also observed consistent up-regulation of PCSK1 levels, an enzyme involved in pro-insulin to insulin processing, in the transcriptome and proteome experiments (**Fig. S6**). Interestingly, we observed an up-regulation of insulin in DIA secretome proteomic at 72 hours after PCSK9 knockdown (**Fig. S6d**). Following PCSK9 knockdown, insulin secretion was impaired: basal and glucose-stimulated insulin secretion increased, while KCl-induced insulin secretion was reduced (**Fig.4d**). Also note that insulin content decreased following PCSK9 knockdown (**Fig. S7**). Gene Ontology Cellular Component enrichment analysis indicated overrepresentation of MHC-I complex and plasma membrane proteins among genes and proteins up-regulated after PCSK9 knockdown (**Fig. 4e**). MHC I complex enrichment was stronger on protein level than on mRNA level. Golgi and endoplasmic reticulum proteins were also up-regulated, which is consistent with the reported role of PCSK9 in intracellular degradation of proteins in the ER-to-Golgi intermediate compartment (22). CD36, CD274 (PDL1) and MHC I complex proteins (particularly HLA-A, B, C and E) were top findings in proteomics experiments (**Fig. 4f, g, h**). ENaC channel subunits were not expressed in EndoC- β H1 cells. LDLR, VLDL, LRP1 and LRP8 levels were not altered (**Fig. S8**). CD81

was up-regulated on mRNA but not protein level (**Fig. S8**). mRNA and whole-cell protein expression of APP and APLP2 was increased after PCSK9 knockdown (**Fig. S8**). Up-regulation of APP and APLP2 mRNA was confirmed by RT-qPCR together with the other top differentially expressed genes (**Fig. 4i**).

PCSK9 knockdown does not affect LDLR levels

In hepatocytes, PCSK9 interacts with LDLR and favors its lysosomal degradation (4). Lack of LDLR dysregulation after PCSK9 knockdown in the omics experiments were unexpected, so we evaluated the effects of exogenously added human recombinant PCSK9 on LDLR expression. Incubating EndoC- β H1 cells with recombinant PCSK9 reduced LDLR protein levels (**Fig. 5a and b**). We also performed a confirmatory siRNA experiment to test whether endogenously produced PCSK9 regulated LDLR expression. PCSK9 knockdown was efficient with a ~80% decrease at the mRNA level (**Fig. 5c**), at the intracellular protein level (for both Pro-PCSK9 and mature PCSK9) (**Fig. 5d, f**) and at the secreted protein level (**Fig. 5e, f**). We next looked at LDLR levels. As expected, PCSK9 knockdown did not modulate LDLR mRNA levels (**Fig. 5g**). Moreover, despite the sharp decrease in PCSK9 protein expression and secretion, PCSK9 knockdown did not impair LDLR protein levels as measured by Western blot (**Fig. 5h and i**). To determine whether PCSK9 specifically modulates LDLR at the cell surface, we performed FACS analyses. Again, PCSK9 knockdown did not modulate cell surface LDLR levels (**Fig. 5j, k**). Taken together, these results indicate that LDLR can be targeted by extracellular PCSK9 but is not regulated by intracellular PCSK9 in EndoC- β H1 cells.

PCSK9 knockdown potentiates the induction of PDL1 and HLA-ABC by interferon- γ

MHC-I and PDL1 are increased in pancreatic islets from type I diabetics and in response to Interferon class I stimulation (39, 40). While characterizing the effect of PCSK9 knockdown on the proteome of EndoC- β H1, we observed up-regulation of MHC-I (particularly HLA-A, B, C and E) and PDL1 (**Fig. 4f, g**). We thus asked whether PCSK9 regulates PDL1 and/or HLA-ABC cell surface expression in basal conditions and following interferon- γ treatment. PCSK9 knockdown consistently reduced *PCSK9* mRNA levels in basal or Interferon- γ stimulated conditions (**Fig. 6a**) with a slight increase of *MHC-I*

mRNA under basal conditions (**Fig. 6b**). On the other hand, upon Interferon- γ treatment, *MHC-I* and *PDL1* mRNA levels were unchanged following PCSK9 knockdown (**Fig. 6b**). We next measured by FACS cell surface expression of PDL1 following siRNA-mediated PCSK9 knockdown or following treatment with recombinant PCSK9. It revealed that while siRNA-mediated PCSK9 knockdown increased cell surface expression of PDL1 (**Fig. 6c, d**), recombinant PCSK9 did not have any effects (**Fig. 6e, f**). We performed a similar experiment, measuring cell surface expression of HLA-ABC. Again, while siRNA-mediated PCSK9 knockdown increased cell surface expression of HLA-ABC (**Fig. 6g, h**), recombinant PCSK9 did not have any effects (**Fig. 6i, j**). This data indicates that PDL1 and HLA-ABC cell surface expression is regulated by intracellular PCSK9.

PCSK9 regulates the expression of VLDLR and CD36, 2 actors involved in fatty acid homeostasis

Fatty acid homeostasis is important for proper beta cell function (Lytrivi et al., 2020). Interestingly, VLDLR and CD36 are involved in the uptake of triglyceride-rich lipoproteins and fatty acids, respectively, and are PCSK9 degradation targets in liver cells (18, 21). We further investigated their expression by RT-qPCR and Western blot. PCSK9 knockdown slightly decreased *VLDLR* mRNA (**Fig. S9a**) but did not impact VLDLR protein expression (**Fig. 7a, b**). Incubating EndoC- β H1 cells with recombinant PCSK9 reduced VLDLR protein expression (**Fig. 7c, d**). PCSK9 knockdown cells exhibited a clear reduction in *PCSK9* mRNA level (**Fig. S9b**) and a slight, but non-statistically significant, increase in *CD36* mRNA level (**Fig. S9c**). FACS analysis revealed a greater than two-fold increase of CD36 cell surface expression (**Fig. 7e, f**). On the other hand, incubating EndoC- β H1 cells with recombinant PCSK9 did not affect CD36 cell surface expression (**Fig. 7g-h**). Finally, upon PCSK9 knockdown, fatty acid uptake increased by 50% (**Fig. 7i**).

In conclusion, both extracellular and intracellular PCSK9 can modulate beta cell fatty acid metabolism through the regulation of VLDLR and CD36 expression respectively.

Discussion

Since its discovery in 2003, numerous studies have addressed PCSK9 expression and function in peripheral organs beyond liver including pancreas (4). PCSK9 mRNA was detected in human and mouse islets, but the cell type(s) expressing PCSK9 protein remained controversial. Moreover, most of the functional studies that address PCSK9 function in pancreatic beta cells focused on LDLR regulation without searching for additional targets (25–29). Here, we hypothesized that PCSK9 is expressed in pancreatic beta cells and that its role may not be restricted to the regulation of LDLR. We demonstrated that beta cells produce and secrete PCSK9. In beta cells, PCSK9 expression is regulated by cholesterol, lipoproteins and by the transcriptional factors SREBPs. In EndoC- β H1, PCSK9 knockdown resulted in transcriptome, proteome and secretome deregulation and increased basal and glucose stimulated insulin secretion. Finally, we observed that in EndoC- β H1, PCSK9 regulates the expression of multiple proteins that included LDLR and VLDLR through extracellular mechanisms, and CD36, HLA-ABC and PDL1 through intracellular mechanisms.

In liver cells, PCSK9 is expressed as a pro-enzyme, processed intracellularly into its mature form and finally secreted (1). By using EndoC- β H1 cells (42), we demonstrated here that it is also the case in human beta cells. Indeed, Western blot analyses detected both Pro-PCSK9 and mature PCSK9 in cell extracts, while only mature PCSK9 was detected in conditioned medium. We noted that the mature PCSK9/PCSK9 total ratio and secreted/intracellular PCSK9 ratio was lower in beta cells compared to liver cells. This suggests that Pro-PCSK9 processing is more efficient in liver cells compared to beta cells and that the intracellular PCSK9 pool is higher in beta cells. This may explain the preferential intracellular regulation of some proteins by PCSK9. The mechanisms that regulate Pro-PCSK9 processing and secretion have only been partially characterized (4). Our results also indicated that PCSK9 processing and secretion might be differentially regulated in liver and beta cells. Beta cells might thus be used as an additional model to study this complex processing.

In liver cells, the transcriptional regulation of PCSK9 has been studied in great detail (4). It has been shown that SREBP2 regulates both basal and statin-induced expression of PCSK9 (6, 43, 44). Interestingly, we demonstrated that in beta cells, physiological PCSK9 levels are regulated by SREBP1, while pharmacological regulation of PCSK9 by Mevastatin is SREBP2-dependent. This was intriguing as in the case of other SREBP1 targets such as *FASN* and *SCD*, we observed a SREBP2 mechanism that compensates for SREBP1-mediated downregulation. This compensatory mechanism was not evident for PCSK9, indicating that physiological levels of PCSK9 in beta cells are highly SREBP1-dependent.

The role of PCSK9 in pancreatic islet function is currently debated. Some studies indicated that PCSK9-deficient mice develop hyperglycemia and insulinopenia (26, 27), while others do not observe this phenotype (25, 28). The reasons for these discrepancies might be linked to the age and/or genetic background of the mice. Here, we observed a sharp decrease in several beta cell enriched transcription factors upon PCSK9 knockdown in EndoC- β H1 cells. It was for example the case for *PDX1* and *NKX6-1* that are known to play major roles in beta cell development and function (45–47). We also detected some perturbation in glucose-stimulated insulin secretion with a specific increase in basal insulin secretion, which was not addressed by Ramin-Mangata *et al.* (29). Taken together, the phenotype observed upon PCSK9 knockdown (decreased expression of specific transcription factors and increased basal insulin secretion) was similar to that observed in immature fetal beta cells (48, 49) and in insulin-producing beta cells differentiated *in vitro* from multipotent stem cells (50, 51). It suggests that PCSK9 might be important to maintain a mature phenotype in pancreatic beta cells.

In mouse islets, loss of beta-cell PCSK9 resulted in unchanged LDLR protein levels (28). Unexpectedly, data from a recently published study (29) indicated that PCSK9 knockdown in EndoC- β H1 cells increased LDLR cell surface expression by 20%. Our data do not support this last claim. We observed, as expected, that exogenously added PCSK9 decreased the expression of LDLR at the cell surface. On the other hand, efficient PCSK9 knockdown did not modify neither *LDLR* mRNA, nor the total

amounts of LDLR protein measured either by Western blot or by global mass spectrometry, nor cell surface LDLR levels measured by FACS. Moreover, we observed similar results when looking at VLDLR, yet another PCSK9 target (18): VLDLR protein levels decreased upon treatment with exogenous PCSK9, without any effect upon PCSK9 knockdown. Our data are consistent with observations in mouse islets (28). The reasons for the discrepancy with Ramin-Mangata et al. (29) are difficult to discuss, as this study presents FACS data in arbitrary units without supporting FACS plots. Taken together, we propose that in pancreatic beta cells, LDLR and VLDLR levels are regulated by PCSK9 extracellularly rather than through intracellular degradation.

CD36 has been described as another PCSK9 target both in mouse liver and in adipocytes (21). There, PCSK9 increased CD36 degradation by a mechanism involving both lysosomes and proteasomes (21). Interestingly, in pancreatic beta cells, inhibiting CD36 has been described as a protective mechanism to prevent excessive lipid accumulation (52), while increased CD36 expression was found to be deleterious for proper beta cell function (53). Here, we observe that PCSK9 knockdown in EndoC- β H1 increased cell surface CD36 expression and fatty acid uptake. Based on RNA-seq and proteomics in PCSK9 knockdown cells and the insensitivity of cell surface CD36 expression to recombinant PCSK9, we postulate that PCSK9 regulates CD36 by an intracellular mechanism. The precise mechanism of this regulation was not identified, but likely involves both proteasomal and lysosomal degradation (21). Further experiments, in particular by using proteasome or lysosome inhibitors are needed to elucidate the nature of CD36 regulation by PCSK9 in the pancreatic beta cell.

In tumoral cells, MHC-I was recently described as a new PCSK9 target, as PCSK9 down regulates MHC-I cell surface expression by increasing its lysosomal degradation and disrupting its recycling (24). In this model, the authors observed marginal effects of PCSK9 on the immune regulatory protein PDL1. Interestingly, MHC-I and PDL1 play major roles in beta cells. Their expressions increases in pancreatic beta cell during inflammatory responses (39, 54) and is also induced in islets from type 1 diabetic patients (39, 54). There, it has been proposed that autoreactive CD8 T cells interact with beta cells

and kill them through an MHC-I mediated activation while PDL1 would be protective against autoimmune injuries (55). Here, we found that PCSK9 knockdown increases both PDL1 and HLA-ABC cell surface expression, particularly upon Interferon- γ stimulation. On the other hand, recombinant PCSK9 did not modulate HLA-ABC and PDL1 levels. We thus proposed that PCSK9 regulates the expression of PDL1 and HLA-ABC in human beta cells by an intracellular mechanism.

In conclusion, we found that PCSK9 is expressed and secreted by human pancreatic beta cells in a tightly regulated manner, which is altered in the presence of statins. In turn, we found that PCSK9 regulates cell surface expression of CD36, PDL1 and HLA-ABC through intracellular mechanisms, but regulates LDLR and VLDLR expression through an extracellular mechanism in pancreatic beta cells. It would be interesting to determine if PCSK9 monoclonal antibodies or siRNA-based therapies against PCSK9 affect expression levels of LDLR and VLDLR, or CD36, PDL1, and HLA-ABC respectively in pancreatic beta cells, and whether co-treatment with statins interfered with the effect of PCSK9 siRNA in the pancreas.

Experimental procedure

Ethical statement

This study was performed according to the Declaration of Helsinki and the Declaration of Istanbul. No tissues were procured from prisoners. Human islets were provided by the Leiden University Medical Center (Leiden, The Netherlands) and the human islet core facility of St-Louis Hospital (Paris, France). They were prepared from pancreata of brain-dead donors after informed consent was signed from next-of-kin, and processed for islet isolation according to the procedures approved by the ethics committee of the French Agency of Biomedicine, and the Dutch national law. All of the animal studies complied with the ARRIVE guidelines and were conducted in strict accordance with the EU Directive 2010/63/EU for animal experiments and with regard to specific national laws and INSERM guidelines.

Culture of EndoC- β H1 cells and treatment

The human pancreatic beta cell line EndoC- β H1 cells (Univercell Biosolutions, Toulouse, France [mycoplasma negative]) was cultured as previously described (42). Experiments were carried out 24 hours after seeding the cells at a density of approximately 10^5 cells /cm². The following compounds were used for treatment: Cholesterol-Methyl- β -Cyclodextrin (C4951, Sigma-Aldrich, France), Mevastatin (M2537, Sigma-Aldrich, Germany), human native LDL and copper oxidized LDL or VLDL (see below for lipoproteins extraction protocol), Human Recombinant Wild Type PCSK9 (Circulex, CY-R2330, Japan).

Human hepatocytes, HepG2 and HEK293T culture

Human primary hepatocytes were isolated from liver fragments obtained from adult patients undergoing partial hepatectomy as previously described (56) and cultured in William's Medium E (Life Technologies) supplemented with 10% FCS (Perbio), 50 μ M hydrocortisone hemisuccinate (SERB laboratory), 5 μ g/ml insulin (Sigma-Aldrich), 2 mM L-glutamine and 200 U/ml penicillin, 200 μ g/ml streptomycin. The human hepatocellular carcinoma cell line HepG2 and the human embryonic kidney

(HEK293T) (mycoplasma free) were cultured in Dulbecco's Modified Eagle's Medium (Gibco) and DMEM/F12 (Gibco), respectively, supplemented with 10 % FCS, 100 units/mL penicillin, and 100 µg/mL streptomycin.

Human islets

Islets were cultured in 12-well plates in CMRL medium supplemented with 10% FCS, HEPES and penicillin/streptomycin (all from Thermo Fisher Scientific). Donor's characteristic and islets details are presented in [Table S1](#).

siRNA transfection

EndoC-βH1 cells were transfected as described (57) in OptiMEM using Lipofectamine RNAiMAX (Life Technologies) with siRNA SMARTpools (Horizon Discovery LTD, UK). Medium was replaced 2.5 hours later with fresh culture medium and analyses were carried out 3 to 6 days following transfection. siRNA reagents used: Control non-targeted siRNA (siCTRL, D-001810-01-20); siRNA targeting: PCSK9 (siPCSK9) (M-005989-01-0005), SREBF-1 (siSREBF-1) (M-006891-00-0005) and SREBF-2 (siSREBF-2) (M-009549-00-0005) at the final concentration of 80 nM.

Cell sorting of mouse alpha, beta and delta cell populations

Alpha, beta and delta cell population were prepared from mouse pancreatic islets as previously described (30).

Lipoproteins preparation and LDL oxidation

LDL and VLDL were extracted from the plasma of healthy volunteers, by sequential ultracentrifugations, as previously described (58). Protein concentration of the lipoproteins was determined by using BCA assay (Pierce). Copper-oxidation of LDL was done by incubating the native LDL with 5 µmol/l CuSO₄ at 37°C for 16 hours followed by dialysis (3 times) against PBS containing 0.1 mM ethylenediamine tetraacetic acid and storage at 4°C.

RNA isolation, reverse transcription, and qPCR

A RNeasy Micro Kit (Qiagen) was used to extract total RNA from EndoC- β H1 cells (59). Genomic DNA was removed by DNase treatment following the RNeasy Micro Kit protocol. RNAs were reverse transcribed by using the Maxima First Strand cDNA kit (Thermo Fisher Scientific). RT-qPCR was performed using Power SYBR Green mix (Applied Biosystems) with a QuantStudio 3 analyzer (Thermo Fisher Scientific). Custom primers were designed with Primer-Blast online, and their efficiency and specificity were determined for each pair by RT-qPCR on a serial dilution of cDNA samples. The list of primers is presented in the [Table S2](#). Relative quantification ($2^{-\Delta\Delta C_t}$) was used to calculate the expression levels of each target gene, normalized to *CYCLOPHILIN-A* transcripts.

Western blot analysis

Western blot experiments were performed as described (59). For VLDLR immunoblot, cell extracts were loaded in 8 % Bis-Tris polyacrylamide gels in absence of heating and 2-beta-mercaptoethanol. The following antibodies were used: PCSK9 (1/200; AF3888; R&D Systems, USA), diluted in TBS 0.1 % Tween with 0,5% BSA; LDLR (1/1,000; ab52818; Abcam), VLDLR (1/1,000; ab75591; Abcam), alpha-Tubulin (1/2,000, T9026; Sigma-Aldrich), beta-actin (1/2,000; A5441; Sigma-Aldrich). Species-specific HRP-linked secondary antibodies (1/1,000; 7074 and 7076; Cell Signaling Technology) were used. Antibodies were validated by knockdown experiments (PCSK9) or have passed application specific testing standards. Densitometric quantification of Western blots was done using ImageJ software and normalized to α -tubulin or β -actin expression.

PCSK9 secretion

EndoC- β H1, HepG2, HEK293T and human islets were cultivated for one hour in their respective culture media free from BSA or FCS. These cells were then cultivated for 24 hours in fresh BSA/FCS-free culture medium. Conditioned media were collected and centrifuged to eliminate cell debris. PCSK9 expression was studied by Western blot on a volume of conditioned medium normalized to

cell count. In the case of human islets, secreted proteins were enriched following precipitation with acetone before Western blot analysis.

Flow cytometry

EndoC- β H1 cells were trypsinized, washed three times in HBSS/1% BSA and incubated at 4 °C for 15 minutes in the dark with the following antibodies: LDLR (1/100; MAB CL 472413; Fisher scientific), CD36 (1/10, 555455, BD Pharmingen), PDL1 (1/100, 329714, Biolegend), HLA-ABC (1/100, 3114410, Biolegend) diluted in HBSS medium/1% BSA (Gibco/Roche Diagnostics). Fluorochrome-conjugated primary antibodies were used with the exception of LDLR detection, for which a step of incubation with Alexa-fluor 488 (1/400, Invitrogen) secondary antibody was performed. Following rinsing in HBSS/1% BSA and incubation with FACS medium containing propidium iodide (1/4,000, Sigma-Aldrich), analysis was carried out using a FACS Aria III (BD Biosciences, San Jose, CA, USA). Dead cells were excluded from analyses by using propidium iodide. Data were analyzed using FlowJo 10.7 software (RRID: RRID:SCR_008520). Results are expressed in mean fluorescence intensities fold changes relative to the control condition.

Insulin secretion

EndoC- β H1 cells were transfected with siControl (siCTRL) or siPCSK9 (siPCSK9). Two days later, cells were starved in DMEM containing 0.5 mM glucose for 24 hours. Then, cells were washed twice and then preincubated in Krebs-Ringer bicarbonate HEPES buffer (KRBH) containing 0.2% fatty acid-free BSA in absence of glucose for 1 hour. Insulin secretion was measured following a 1-hour incubation with KRBH containing 0.2% fatty acid-free BSA and 0 mM or 20 mM glucose, or 50 mM KCl. Insulin secretion and intracellular insulin were measured by ELISA as previously described (42).

Fatty acid uptake

Fatty acid uptake in EndoC- β H1 was studied using the Fatty Acid Uptake Kit (MAK156, Sigma-Aldrich, Germany). Cells were transfected with siControl (siCTRL) or siPCSK9 (siPCSK9). Six days later, cells

were starved for 1 hour in cell culture medium free from BSA. TF2-C12 fluorescent fatty acid was added to the culture medium for 1 hour. Fluorescence signal was measured at $\lambda_{\text{exc}}=485\text{nm}/\lambda_{\text{em}}=520\text{nm}$ and normalized to cell count. Fatty acid uptake was calculated by subtracting the fluorescence intensity measured at 1 hour incubation by that measured at time point zero, following the manufacturer's instructions. Results were expressed in fatty acid uptake fold changes relative to control.

RNA-seq and proteomics analyses

Acquisition of proteomics and RNA-seq data and sample size calculation for omics experiments have been previously described (35). Benjamini-Yekutielli method (60) was used to adjust for multiple testing for IPA Pathway terms due to non-ignorable overlap between genes underlying top pathways. Gene set enrichment analysis was conducted with GSEA v4.0.3 software (RRID: SCR_003199).

Statistical analysis of RT-qPCR, Western blot and FACS experiments

Each n represents an independent experiment. All of the graphs show means +/- Standard Error of the Mean (SD) and the statistical analysis were conducted using Prism (GraphPad, San Diego, CA, USA) either with t-test if the normality condition was respected or with the non-parametric equivalent Mann-Whitney test. A p -value less than 0.05 was considered significant and Symbols for indicating p -values are * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.005$.

Data availability

The datasets generated during and/or analyzed during the current study were previously published (35) and are available from the corresponding authors.

RNA-seq data have been deposited to GEO database with accession number GSE182016. Mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the following identifiers: PXD027921, PXD027911 and PXD027913.

Supporting information-This article contains supporting information.

Acknowledgments

The authors thank Natascha de Graaf (LUMC) for technical support. We would like to thank Latif Rachdi for helpful discussions.

Author contributions

K.S., G.H., I.G. and C.B. performed experiments. M.A. and F.C. provided human islets. K.S., R.S., M.R. and A.J. analyzed data and drafted the manuscript with contributions from S.A., W.L.G., K.SG, C.R.U.

All authors approved the final draft.

Funding and additional information

The RS laboratory is supported by grants from the Fondation pour la Recherche Médicale (EQU201903007793), the Dutch Diabetes Research Foundation, the DON Foundation, the Fondation Francophone pour la Recherche sur le Diabetes (FFRD), the Agence Nationale de la Recherche (ANR-19-CE15-0014-01), Laboratoire d'Excellence consortium Revive, the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115797 (INNODIA) and no. 945268 (INNODIA HARVEST). This joint undertaking receives support from the Union's Horizon 2020 research and innovation program EFPIA, JDRF, and the Leona M. and Harry B. Helmsley Charitable Trust, from.

Conflict of interest

S.A., K.Se., M.R., A.J., C.R.U and G.H. are employed by AstraZeneca. R.S. is a shareholder in and consultant for Univercell-Biosolutions.

References

1. Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., and Chretien, M. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. *Proc. Natl. Acad. Sci. U. S. A.* **100**, 928–933
2. GTEx Consortium (2020) The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science.* **369**, 1318–1330
3. Zaid, A., Roubtsova, A., Essalmani, R., Marcinkiewicz, J., Chamberland, A., Hamelin, J., Tremblay, M., Jacques, H., Jin, W., Davignon, J., Seidah, N. G., and Prat, A. (2008) Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. *Hepatology. Baltim. Md.* **48**, 646–654
4. Seidah, N. G., Awan, Z., Chrétien, M., and Mbikay, M. (2014) PCSK9: a key modulator of cardiovascular health. *Circ. Res.* **114**, 1022–1036
5. Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N. G., Bernier, L., and Prat, A. (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. *Arterioscler. Thromb. Vasc. Biol.* **24**, 1454–1459
6. Jeong, H. J., Lee, H.-S., Kim, K.-S., Kim, Y.-K., Yoon, D., and Park, S. W. (2008) Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. *J. Lipid Res.* **49**, 399–409
7. Costet, P., Cariou, B., Lambert, G., Lalanne, F., Lardeux, B., Jarnoux, A.-L., Grefhorst, A., Staels, B., and Krempf, M. (2006) Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. *J. Biol. Chem.* **281**, 6211–6218
8. Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., and Boileau, C. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat. Genet.* **34**, 154–156
9. Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., and Hobbs, H. H. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. *Nat. Genet.* **37**, 161–165
10. Seidah, N. G., Prat, A., Pirillo, A., Catapano, A. L., and Norata, G. D. (2019) Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. *Cardiovasc. Res.* **115**, 510–518
11. Lamb, Y. N. (2021) Inclisiran: First Approval. *Drugs.* **81**, 389–395
12. Schmidt, A. F., Swerdlow, D. I., Holmes, M. V., Patel, R. S., Fairhurst-Hunter, Z., Lyall, D. M., Hartwig, F. P., Horta, B. L., Hyppönen, E., Power, C., Moldovan, M., van Iperen, E., Hovingh, G. K., Demuth, I., Norman, K., Steinhagen-Thiessen, E., Demuth, J., Bertram, L., Liu, T., Coassin, S., Willeit, J., Kiechl, S., Willeit, K., Mason, D., Wright, J., Morris, R., Wanamethee, G., Whincup, P., Ben-Shlomo, Y., McLachlan, S., Price, J. F., Kivimaki, M., Welch, C., Sanchez-Galvez, A., Marques-Vidal, P., Nicolaidis, A., Panayiotou, A. G., Onland-Moret, N. C., van der Schouw, Y. T., Matullo, G., Fiorito, G., Guarrera, S., Sacerdote, C., Wareham, N. J., Langenberg, C., Scott, R., Luan, J., Bobak, M., Malyutina, S., Paják, A., Kubinova, R., Tamosiunas, A., Pikhart, H., Husemoen, L. L. N., Grarup, N., Pedersen, O., Hansen, T., Linneberg, A., Simonsen, K. S., Cooper, J., Humphries, S. E., Brilliant, M., Kitchner, T., Hakonarson, H., Carrell, D. S., McCarty, C. A., Kirchner, H. L., Larson, E. B., Crosslin, D. R., de Andrade, M., Roden, D. M., Denny, J. C., Carty, C., Hancock, S., Attia, J., Holliday, E., O'Donnell, M., Yusuf, S., Chong, M., Pare, G., van der Harst, P., Said, M. A., Eppinga, R. N., Verweij, N., Snieder, H., LifeLines Cohort study group, Christen, T., Mook-Kanamori, D. O., Gustafsson, S., Lind, L., Ingelsson, E., Pazoki, R., Franco, O., Hofman, A., Uitterlinden, A., Dehghan, A., Teumer, A., Baumeister, S., Dörr, M., Lerch, M. M., Völker, U.,

- Völzke, H., Ward, J., Pell, J. P., Smith, D. J., Meade, T., Maitland-van der Zee, A. H., Baranova, E. V., Young, R., Ford, I., Campbell, A., Padmanabhan, S., Bots, M. L., Grobbee, D. E., Froguel, P., Thuillier, D., Balkau, B., Bonnefond, A., Cariou, B., Smart, M., Bao, Y., Kumari, M., Mahajan, A., Ridker, P. M., Chasman, D. I., Reiner, A. P., Lange, L. A., Ritchie, M. D., Asselbergs, F. W., Casas, J.-P., Keating, B. J., Preiss, D., Hingorani, A. D., UCLEB consortium, and Sattar, N. (2017) PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. *Lancet Diabetes Endocrinol.* **5**, 97–105
13. Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Loizeau, V., Lopes, R. D., Moryusef, A., Murin, J., Porady, R., Ristic, A. D., Roe, M. T., Tuñón, J., White, H. D., Zeiher, A. M., Schwartz, G. G., Steg, P. G., and ODYSSEY OUTCOMES Committees and Investigators (2019) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. *Lancet Diabetes Endocrinol.* **7**, 618–628
 14. Sattar, N., Toth, P. P., Blom, D. J., Koren, M. J., Soran, H., Uhart, M., Elliott, M., Cyrille, M., Somaratne, R., and Preiss, D. (2017) Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. *Am. J. Cardiol.* **120**, 1521–1527
 15. Nassoury, N., Blasiolo, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., and Seidah, N. G. (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. *Traffic Cph. Den.* **8**, 718–732
 16. Park, S. W., Moon, Y.-A., and Horton, J. D. (2004) Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. *J. Biol. Chem.* **279**, 50630–50638
 17. Poirier, S., Mayer, G., Poupon, V., McPherson, P. S., Desjardins, R., Ly, K., Asselin, M.-C., Day, R., Duclos, F. J., Witmer, M., Parker, R., Prat, A., and Seidah, N. G. (2009) Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. *J. Biol. Chem.* **284**, 28856–28864
 18. Poirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nassoury, N., Mayer, H., Nimpf, J., Prat, A., and Seidah, N. G. (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. *J. Biol. Chem.* **283**, 2363–2372
 19. Labonté, P., Begley, S., Guévin, C., Asselin, M.-C., Nassoury, N., Mayer, G., Prat, A., and Seidah, N. G. (2009) PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. *Hepatol. Baltim. Md.* **50**, 17–24
 20. Canuel, M., Sun, X., Asselin, M.-C., Paramithiotis, E., Prat, A., and Seidah, N. G. (2013) Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). *PloS One.* **8**, e64145
 21. Demers, A., Samami, S., Lauzier, B., Des Rosiers, C., Ngo Sock, E. T., Ong, H., and Mayer, G. (2015) PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver. *Arterioscler. Thromb. Vasc. Biol.* **35**, 2517–2525
 22. Jonas, M. C., Costantini, C., and Puglielli, L. (2008) PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. *EMBO Rep.* **9**, 916–922
 23. Sharotri, V., Collier, D. M., Olson, D. R., Zhou, R., and Snyder, P. M. (2012) Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). *J. Biol. Chem.* **287**, 19266–19274
 24. Liu, X., Bao, X., Hu, M., Chang, H., Jiao, M., Cheng, J., Xie, L., Huang, Q., Li, F., and Li, C.-Y. (2020) Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. *Nature.* **588**, 693–698
 25. Langhi, C., Le May, C., Gmyr, V., Vandewalle, B., Kerr-Conte, J., Krempf, M., Pattou, F., Costet, P., and Cariou, B. (2009) PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. *Biochem. Biophys. Res. Commun.* **390**, 1288–1293

26. Mbikay, M., Sirois, F., Mayne, J., Wang, G.-S., Chen, A., Dewpura, T., Prat, A., Seidah, N. G., Chretien, M., and Scott, F. W. (2010) PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. *FEBS Lett.* **584**, 701–706
27. Da Dalt, L., Ruscica, M., Bonacina, F., Balzarotti, G., Dhyani, A., Di Cairano, E., Baragetti, A., Arnaboldi, L., De Metrio, S., Pellegatta, F., Grigore, L., Botta, M., Macchi, C., Ubaldi, P., Perego, C., Catapano, A. L., and Norata, G. D. (2019) PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. *Eur. Heart J.* **40**, 357–368
28. Peyot, M.-L., Roubtsova, A., Lussier, R., Chamberland, A., Essalmani, R., Murthy Madiraju, S. R., Seidah, N. G., Prentki, M., and Prat, A. (2021) Substantial PCSK9 inactivation in β -cells does not modify glucose homeostasis or insulin secretion in mice. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids.* **1866**, 158968
29. Ramin-Mangata, S., Thedrez, A., Nativel, B., Diotel, N., Blanchard, V., Wargny, M., Aguesse, A., Billon-Crossouard, S., Vindis, C., Le May, C., Hulin, P., Armanet, M., Gmyr, V., Pattou, F., Croyal, M., Meilhac, O., Nobécourt, E., Cariou, B., and Lambert, G. (2021) Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. *Atherosclerosis.* **326**, 47–55
30. Berthault, C., Staels, W., and Scharfmann, R. (2020) Purification of pancreatic endocrine subsets reveals increased iron metabolism in beta cells. *Mol. Metab.* **42**, 101060
31. Segerstolpe, Å., Palasantza, A., Eliasson, P., Andersson, E.-M., Andréasson, A.-C., Sun, X., Picelli, S., Sabirsh, A., Clausen, M., Bjursell, M. K., Smith, D. M., Kasper, M., Ämmälä, C., and Sandberg, R. (2016) Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes. *Cell Metab.* **24**, 593–607
32. Xin, Y., Kim, J., Okamoto, H., Ni, M., Wei, Y., Adler, C., Murphy, A. J., Yancopoulos, G. D., Lin, C., and Gromada, J. (2016) RNA Sequencing of Single Human Islet Cells Reveals Type 2 Diabetes Genes. *Cell Metab.* **24**, 608–615
33. Lawlor, N., George, J., Bolisetty, M., Kursawe, R., Sun, L., Sivakamasundari, V., Kycia, I., Robson, P., and Stitzel, M. L. (2017) Single-cell transcriptomes identify human islet cell signatures and reveal cell-type-specific expression changes in type 2 diabetes. *Genome Res.* **27**, 208–222
34. Blodgett, D. M., Nowosielska, A., Afik, S., Pechhold, S., Cura, A. J., Kennedy, N. J., Kim, S., Kucukural, A., Davis, R. J., Kent, S. C., Greiner, D. L., Garber, M. G., Harlan, D. M., and dilorio, P. (2015) Novel Observations From Next-Generation RNA Sequencing of Highly Purified Human Adult and Fetal Islet Cell Subsets. *Diabetes.* **64**, 3172–3181
35. Ryaboshapkina, M., Saitoski, K., Hamza, G. M., Jarnuczak, A. F., Pechberty, S., Berthault, C., Sengupta, K., Underwood, C. R., Andersson, S., and Scharfmann, R. (2022) Characterization of the Secretome, Transcriptome, and Proteome of Human β Cell Line EndoC- β H1. *Mol. Cell. Proteomics MCP.* **21**, 100229
36. Maxwell, K. N., Soccio, R. E., Duncan, E. M., Sehayek, E., and Breslow, J. L. (2003) Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. *J. Lipid Res.* **44**, 2109–2119
37. Maechler, P. (2013) Mitochondrial function and insulin secretion. *Mol. Cell. Endocrinol.* **379**, 12–18
38. Taneera, J., Fadista, J., Ahlqvist, E., Atac, D., Ottosson-Laakso, E., Wollheim, C. B., and Groop, L. (2015) Identification of novel genes for glucose metabolism based upon expression pattern in human islets and effect on insulin secretion and glycemia. *Hum. Mol. Genet.* **24**, 1945–1955
39. Colli, M. L., Hill, J. L. E., Marroquí, L., Chaffey, J., Dos Santos, R. S., Leete, P., Coomans de Brachène, A., Paula, F. M. M., Op de Beeck, A., Castela, A., Marselli, L., Krogvold, L., Dahl-Jorgensen, K., Marchetti, P., Morgan, N. G., Richardson, S. J., and Eizirik, D. L. (2018) PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons- α and γ via IRF1 induction. *EBioMedicine.* **36**, 367–375
40. Foulis, A. K., Farquharson, M. A., and Hardman, R. (1987) Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major

- histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus. *Diabetologia*. **30**, 333–343
41. Lytrivi, M., Castell, A.-L., Poitout, V., and Cnop, M. (2020) Recent Insights Into Mechanisms of β -Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes. *J. Mol. Biol.* **432**, 1514–1534
 42. Ravassard, P., Hazhouz, Y., Pechberty, S., Bricout-Neveu, E., Armanet, M., Czernichow, P., and Scharfmann, R. (2011) A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion. *J. Clin. Invest.* **121**, 3589–3597
 43. Li, H., Dong, B., Park, S. W., Lee, H.-S., Chen, W., and Liu, J. (2009) Hepatocyte nuclear factor 1 α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. *J. Biol. Chem.* **284**, 28885–28895
 44. Miyosawa, K., Watanabe, Y., Murakami, K., Murakami, T., Shibata, H., Iwashita, M., Yamazaki, H., Yamazaki, K., Ohgiya, T., Shibuya, K., Mizuno, K., Tanabe, S., Singh, S. A., and Aikawa, M. (2015) New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism. *Am. J. Physiol. Endocrinol. Metab.* **309**, E177-190
 45. Jennings, R. E., Scharfmann, R., and Staels, W. (2020) Transcription factors that shape the mammalian pancreas. *Diabetologia*. **63**, 1974–1980
 46. Oliver-Krasinski, J. M., and Stoffers, D. A. (2008) On the origin of the beta cell. *Genes Dev.* **22**, 1998–2021
 47. Servitja, J. M., and Ferrer, J. (2004) Transcriptional networks controlling pancreatic development and beta cell function. *Diabetologia*. **47**, 597–613
 48. Blum, B., Hrvatin, S., Schuetz, C., Bonal, C., Rezaia, A., and Melton, D. A. (2012) Functional beta-cell maturation is marked by an increased glucose threshold and by expression of urocortin 3. *Nat. Biotechnol.* **30**, 261–264
 49. van der Meulen, T., and Huising, M. O. (2014) Maturation of stem cell-derived beta-cells guided by the expression of urocortin 3. *Rev. Diabet. Stud. RDS.* **11**, 115–132
 50. Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Greiner, D., and Melton, D. A. (2014) Generation of functional human pancreatic β cells in vitro. *Cell.* **159**, 428–439
 51. Rezaia, A., Bruin, J. E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O’Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., Yang, Y. H. C., Johnson, J. D., and Kieffer, T. J. (2014) Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. *Nat. Biotechnol.* **32**, 1121–1133
 52. Khan, S., and Kowluru, A. (2018) CD36 mediates lipid accumulation in pancreatic beta cells under the duress of glucolipotoxic conditions: Novel roles of lysine deacetylases. *Biochem. Biophys. Res. Commun.* **495**, 2221–2226
 53. Nagao, M., Esguerra, J. L. S., Asai, A., Ofori, J. K., Edlund, A., Wendt, A., Sugihara, H., Wollheim, C. B., Oikawa, S., and Eliasson, L. (2020) Potential Protection Against Type 2 Diabetes in Obesity Through Lower CD36 Expression and Improved Exocytosis in β -Cells. *Diabetes*. **69**, 1193–1205
 54. Thomas, H. E., Parker, J. L., Schreiber, R. D., and Kay, T. W. (1998) IFN- γ action on pancreatic beta cells causes class I MHC upregulation but not diabetes. *J. Clin. Invest.* **102**, 1249–1257
 55. Roep, B. O., Thomaidou, S., van Tienhoven, R., and Zaldumbide, A. (2021) Type 1 diabetes mellitus as a disease of the β -cell (do not blame the immune system?). *Nat. Rev. Endocrinol.* **17**, 150–161
 56. Silvie, O., Rubinstein, E., Franetich, J.-F., Prenant, M., Belnoue, E., Rénia, L., Hannoun, L., Eling, W., Levy, S., Boucheix, C., and Mazier, D. (2003) Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. *Nat. Med.* **9**, 93–96
 57. Oshima, M., Knoch, K.-P., Diedisheim, M., Petzold, A., Cattan, P., Bugliani, M., Marchetti, P., Choudhary, P., Huang, G.-C., Bornstein, S. R., Solimena, M., Albagli-Curiel, O., and Scharfmann, R. (2018) Virus-like infection induces human β cell dedifferentiation. *JCI Insight.* **3**, 97732
 58. Redgrave, T. G., Roberts, D. C., and West, C. E. (1975) Separation of plasma lipoproteins by density-gradient ultracentrifugation. *Anal. Biochem.* **65**, 42–49

59. Rachdi, L., Maugein, A., Pechberty, S., Armanet, M., Hamroune, J., Ravassard, P., Marullo, S., Albagli, O., and Scharfmann, R. (2020) Regulated expression and function of the GABAB receptor in human pancreatic beta cell line and islets. *Sci. Rep.* **10**, 13469
60. Benjamini, Y., and Yekutieli, D. (2001) The control of the false discovery rate in multiple testing under dependency. *Ann. Stat.* 10.1214/aos/1013699998

Figure legends

Figure 1: PCSK9 is expressed and secreted by pancreatic beta cells

(a-c) *PCSK9* mRNA expression in: (a) mouse liver compared to FACS-enriched pancreatic beta, delta and alpha endocrine fractions ($n=4-5$); (b) human islets, hepatocytes and HEK293T cells ($n=5-8$); (c) EndoC- β H1, HepG2 and HEK293T cells ($n=6-7$). (d, e) Detection by Western blot and quantification of intracellular PCSK9 in EndoC- β H1, HepG2 and HEK293T cells ($n=5$). (f, g) Detection by Western blot and quantification of secreted PCSK9 in EndoC- β H1, HepG2 and HEK293T cells ($n=5-6$). (h) Western blot analysis of PCSK9 secretion by human islets, compared to HEK293T cells ($n=7$). Data represent the means \pm SD. * $p < 0.05$, ** $p < 0.01$

Figure 2: Cholesterol, LDL and Mevastatin modulate PCSK9 expression and secretion

(a-f) EndoC- β H1 cells were exposed to 10 μ g/ml human LDL, 0.25 mM Cholesterol-methyl- β -cyclodextrin, and 10 μ g/ml Mevastatin for 24 hours. (a, b) SREBP-2 transcriptional targets (*HMGCR* and *LDLR*), SREBP-1 transcriptional targets (*FASN*, and *SCD*) and PCSK9 mRNA were measured by RT-qPCR ($n=5$). Intracellular (c, d) and secreted (e, f) PCSK9 were analyzed and quantified by Western blot ($n=4$). (g, h) EndoC- β H1 cells were exposed to 10 μ g/ml native LDL, oxidized LDL or Triglyceride-Rich Lipoproteins (TRL) for 24 hours. *PCSK9*, SREBP1 and SREBP2 targets were measured by RT-qPCR. ($n=4$) Data represent the means \pm SD. * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$

Figure 3: PCSK9 is regulated by the SREBPs-1 and 2 transcription factors

(a-c) EndoC- β H1 cells were transfected with control nontarget siRNA (siCtrl), siRNA targeting SREBP-1+SREBP-2 (siSREBP-1+2), SREBP-2 (siSREBP-2), or SREBP-1 (siSREBP-1). RT-qPCR for SREBP's and their targets were performed 3 days later ($n=5$). (d-g) EndoC- β H1 cells were transfected with siRNA, cultured for 72h and next treated for 24 hours with DMSO (control) or Mevastatin before analyses by RT-qPCR ($n=5$). Data represent the means \pm SD. * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$

Figure 4: Insights from omics experiments

EndoC- β H1 cells were transfected with control nontarget siRNA (siControl) or siRNA targeting PCSK9 (siPCSK9). Three days later, cells were profiled by RNA-seq and proteomics. RNA-seq data were analyzed with: (a) Ingenuity Pathway Analysis (IPA) software, for the top enriched canonical pathways, and (b) Gene Set Enrichment Analysis (GSEA) software with the Hallmark_Oxidative_Phosphorylation gene set. (c) GSIS markers deregulated upon PCSK9 knockdown with FDR <0.05 in RNA-seq experiment. (d) Basal (0.5 mM), glucose-stimulated (20 mM) and KCl-stimulated (50 mM) insulin secretion was measured in EndoC- β H1 cells, three days following PCSK9 knockdown ($n=6$). (e) Gene Ontology analysis of cellular components terms enriched among genes and proteins up-regulated following PCSK9 knockdown. (f-h) Boxplot showing protein expression of top candidate PCSK9 degradation targets, measured on cell protein extracts by DIA and TMT proteomic. (i) RT-qPCR validation of selected top differentially expressed genes ($n=10$). For GSIS and RT-qPCR analyses, data are presented as means \pm SD. For proteomics experiments, median expression and interquartile ranges are shown. + FDR < 0.05, * p < 0.05, ** p < 0.01 and *** p < 0.001

Figure 5: PCSK9 knockdown does not affect LDLR levels

(a, b): EndoC- β H1 cells were exposed for 16 hours to human recombinant PCSK9 (2.5 μ g/ml). LDLR protein expression was studied by Western blot and quantified ($n=4$). (c-k) EndoC- β H1 cells were transfected with control nontarget siRNA (siCtrl) or siRNA targeting PCSK9 (siPCSK9). Analyses were performed 3 days later. (c-f) PCSK9 knockdown efficiency was analyzed by RT-qPCR ($n=9$) (c) and Western blot for intracellular and secreted PCSK9 ($n=5-7$) (d-f). (g-k) The effect of PCSK9 knockdown on LDLR was measured by RT-qPCR, ($n=7$), Western blot ($n=5$) and by FACS for cell surface expression ($n=6$). Data represent the means \pm SD. * p < 0.05, ** p < 0.01 and *** p < 0.001

Figure 6: PCSK9 knockdown potentiates the induction of PDL1 and HLA-ABC by interferon- γ

(a-d) EndoC- β H1 cells were transfected with control nontarget siRNA (siCtrl) or siRNA targeting PCSK9 (siPCSK9). Five days later, the cells were incubated for 24 hours with 500 U/ml interferon- γ (IFN- γ). (a, b), RT-qPCR analysis of PCSK9, PDL1 and MHC- I ($n=6-7$) (c, d) Cell surface PDL1

expression analyzed by FACS ($n=8-9$). **(e, f)** EndoC- β H1 cells were treated with 500 U/ml interferon- γ (IFN- γ). Twenty-four hours later, human recombinant PCSK9 (rPCSK9) (2.5 μ g/ml) was added to the culture medium for 16 hours. Cell surface PDL1 was studied by FACS ($n=4$). **(g-j)** Cell surface HLA-ABC expression analyzed by FACS under the same experimental conditions as in (a-f) ($n=4-7$). Data represent the means \pm SD. * $p < 0.05$, ** $p < 0.01$

Figure 7: PCSK9 regulates the expression of VLDLR and CD36, 2 actors involved in fatty acid homeostasis

(a, b) EndoC- β H1 cells were transfected with control nontarget siRNA (siCtrl) or siRNA targeting PCSK9. Three days later, VLDLR expression was studied by Western blot and quantified ($n=5-6$). **(c, d)** EndoC- β H1 cells were exposed for 16 hours to human recombinant PCSK9 (2.5 μ g/ml) and VLDLR protein expression was studied by Western blot ($n=4$). **(e, f)**: EndoC- β H1 were transfected with siRNA (siCtrl) or siRNA targeting PCSK9. Six days later, cell surface CD36 was analyzed by FACS ($n=4$). **(g, h)** EndoC- β H1 cells were exposed for 16 hours to 2.5 μ g/ml human recombinant PCSK9 and cell surface CD36 was analyzed by FACS ($n=4$). **(i)** Fatty acid uptake was evaluated six days following PCSK9 knockdown ($n=10$). Data represent the means \pm SD. * $p < 0.05$, *** $p < 0.001$

Fig. 1




Fig. 2






Fig. 3


a




b




c



d



e



f



g




Fig. 4













Fig. 5


a




b




c




d




e




f




g




h



i



j



k






Fig. 6


a




b




c




d




e




f




g



h



i



j




Fig. 7

